TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Grand Autohemo-Therapy With Oxygen-ozone on Patients With Hypertonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Resistant Hypertension \> 140 / \> 90mmHg~* Inclusion age : 45 +~* Regular monitoring of blood levels considered~* pre-medication to lower blood pressure for at least 3 weeks before the preliminary investigation consistent~* Men and Women~Exclusion Criteria:~* derailed diabetes~* renal impairment , renal creatinine clear \<50 ml~* Non - austherapierte cancer / tumor patients~* Non - adjusted thyroid dysfunction~* BMI\> 35~* LVEF \<limit (  35%  )~* Peripheral AVK ( ABI - measurement ) \> Stage II~* regurgitation \> Stage I~* abdominal aneurysm~* infections~* acute febrile infections with temperature \> 38.5 ° C~* COPD and asthma to stage III~* dyspnea NYHA \> Stage III~* z.n. Stroke shorter than 12 weeks~* Acute liver failure~* Acute Apoplexy~* Severe poisoning~* drug addiction~* hyperthyroidism~* Hypotension~* hypocalcemia~* hypoglycemia~* ozone allergy~* pregnancy~* clotting problems ( hemophilia )~* pre-existing condition with hemoglobin \< 9mg/dl~* Fresh myocardial infarction~* Internal bleeding~* thrombocytopenia~* Acute alcohol~* Citrus allergy when using sodium citrate

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Nitric Oxide Metabolites for Predicting Embryo Quality in In-Vitro Fertilization (IVF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21-37~* Female~* Less than two previous unsuccessful IVF cycles~Exclusion Criteria:~* Day 3 FSH \>9.9~* Fewer than 8 mature oocytes retrieved~* Fewer than 8 normally fertilized embryos on day 2 after fertilization

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 37 Years
- Healthy Volunteers: t

Study Arms:
- Day 3 transfer (Type: ACTIVE_COMPARATOR): Subjects in this arm will have two embryos transferred three days after fertilization. Embryos will be selected based on the concentration of nitric oxide metabolites in the culture medium.
- Day 5 transfer (Type: ACTIVE_COMPARATOR): Subjects will have two embryos transferred on day 5 after fertilization with selection of embryos based on morphologic criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Must have at least 1 biopsy-proven nonmelanoma skin cancer with a minimum diameter of 4 mm~* No tumors located on the eyelids, distal nose, cartilaginous portions of the ears, or lips~PATIENT CHARACTERISTICS:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known hypersensitivity to aminolevulinic acid or any component of this medication~PRIOR CONCURRENT THERAPY:~* Concurrent immunosuppressive or chemotherapeutic medications allowed~* Concurrent corticosteroids (taken by mouth or large doses taken with an inhaler) allowed~* Concurrent systemic retinoids (e.g., isotretinoin, acitretin, bexarotene, alitretinoin) or vitamin A allowed~* Other concurrent medications that may affect epidermal growth and differentiation (e.g., anti-EGFR monoclonal antibodies) allowed~* No concurrent participation in another clinical trial~* No concurrent topical treatment for the target tumor or for other nonmelanoma skin cancers~* No concurrent medical therapy or radiotherapy for other cancers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: CoQun Study - (COQUN): a Study to Evaluate the Effects of CoQun in Patients Affected by Open-angle Glaucoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with diagnosis of POAG (monolateral or bilateral) with an IOP ranging from 17 to 21 mm Hg (at the last performed visit and confirmed at the baseline study visit) on treatment with a topical prostaglandin analogue (PGA) monotherapy.~2. VF examination at randomization: VF Mean Defect (MD) at baseline within -4 decibel (dB) and -10dB and VF Pattern Standard Deviation (PSD) within 4 dB and 10dB (stage 2-3 per the Enhanced Glaucoma Staging System 2 (GSS) determined by Humphrey Field Analyzer II-i, program 30-2 SITA standard.~3. In order to determine patient's reliability to perform VF examination: before baseline VF, at least two reliable VF examinations during the last year had to be performed. Visual fields are considered reliable if false-positive responses are fewer than 15% and a clear blind spot could be seen in the VF printouts, threshold value \<10 dB.~4. Age \>40 years~5. Provision of informed consent prior to any study specific procedures~Exclusion Criteria:~1. Secondary glaucoma (exofoliative glaucoma, pigmentary glaucoma, neovascular glaucoma).~2. Abnormalities of the anterior segment of the eye that could affect IOP assessment.~3. Cornea abnormalities with entities that could affect IOP evaluation.~4. Other conditions different from glaucoma that could cause VF abnormalities (degenerative myopia, diabetic retinopathy, maculopathy, other optic nerve abnormalities that could mimic glaucoma damage).~5. BCVA) \< 0.5 Snellen decimal fraction~6. Any previous ocular surgery except for uncomplicated cataract extraction and YAG laser capsulotomy, laser glaucoma surgeries (argon laser trabeculoplasty and/or selective laser trabeculoplasty).~7. Pregnancy or breast-feeding.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- CoQun® (Type: EXPERIMENTAL): Patients in Arm A will be randomized to receive Prostaglandin analogue (PGA) monotherapy + CoQun®. CoQun® ophthalmic solution will be administered two times daily. CoQun® will be administered in addition to hypotensive therapy. Dose modifications for CoQun® are not permitted.
- Placebo (Type: PLACEBO_COMPARATOR): Patients in Arm B will be randomized to receive Prostaglandin analogue (PGA) monotherapy +Placebo. Placebo ophthalmic solution will be administered two times daily. Placebo will be administered in addition to hypotensive therapy. Dose modifications for Placebo are not permitted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with breast cancer, at a disseminated stage~* patients treated with bevacizumab in combination with weekly paclitaxel as first line chemotherapy and who have progressed~* alive patients authorizing the extraction and analysis of their biological samples.~Exclusion Criteria:~* patients with a second neoplasia~* deceased patients~* patients who have not agreed to participate in the study~* HER2 positive patients~* patients with CNS metastases when first treated with bevacizumab in combination with paclitaxel~* patients with local-regional recurrence only and~* patients with status NED (resected metastases)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Spectacles Lens in Concussed Kids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Sustained a concussion \> 6 weeks \< 16 weeks from date of initial visit~* Criteria for concussion: formally diagnosed by physician~* Minimum best corrected visual acuity: 20/25 in right and left eyes at distance and 20/30 both eyes at near~* Minimum Stereopsis: 500 global~* CISS score \> 16~* Refractive error at least + 0.50D sphere or cylinder~* Ability to clear \> 0.50 cycles per minute in monocular accommodative flipper of and binocular accommodative flipper of +/-1.50~Exclusion Criteria:~* Diplopia from nerve palsies~* Retinal pathology~* Previous treatment of any amount of bifocal lenses and base in prism since concussion.~* Vision therapy \> 6 weeks since concussion

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Single vision glasses (Type: EXPERIMENTAL): Typical glasses prescribed for children to correct only distance refractive error and to be worn all waking hours.
- Single vision glasses with anti-glare coating (Type: EXPERIMENTAL): Typical glasses prescribed for children to correct only distance prescription with anti-glare coating and to be worn all waking hours.
- Eyezen (Type: EXPERIMENTAL): Commercially available, low-powered, progressive addition lenses glasses with anti-glare coating to be worn all waking hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Atrioventricular Node Ablation in Patients With Atrial Fibrillation and Moderate Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18-75 years~* CHF II-III NYHA~* Persistent/permanent AF requiring AV node ablation~* LVEF \< 45%~* Signed informed consent~* Able to complete all testing required by the clinical protocol~Exclusion Criteria:~* Myocardial infarction or stroke less than 3 months prior to randomization~* Patients who require revascularization, radiofrequency ablation of pulmonary veins and substrate of AF~* The congenital and acquired heart diseases, LV aneurysm, which requires a surgical correction~* Active inflammatory and autoimmune diseases of a myocardium~* The thyrotoxicosis~* The diseases that limit life expectancy (cancer, tuberculosis, etc.)~* Contraindications to anticoagulants administration at CHADS2\> 2~* Uncompliant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CRT (Type: EXPERIMENTAL): None
- pacemaker (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sildenafil and Pulmonary Artery Pressure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Candidates for enrollment in this clinical trial are limited to adult patients diagnosed with severe portopulmonary hypertension (PTPH). Specifically, other causes of pulmonary hypertension (PH) such as left ventricular dysfunction, valvular heart disease, chronic lung disease, chronic thromboembolic disease, chronic hypoxemia, rheumatologic conditions, and significant untreated obstructive sleep apnea will be excluded in the usual fashion in patients with underlying portal hypertension and usually cirrhosis. The diagnosis of pulmonary hypertension will be confirmed by invasive hemodynamic measurements (i.e. right heart catheterization) and severe PH is defined as a mean pulmonary artery pressure (MPAP) \>35 mmHg. If evidence of right ventricular (RV) dysfunction is present (RV dilation, reduced RV ejection fraction (EF), or elevated RV end-diastolic pressure (\>10 mmHg) and the MPAP is 30-35 mmHg, then the patient may be enrolled.~Study participants will be selected from those patients referred for hemodynamic assessment of pulmonary hypertension, such as potential liver transplant recipients. They must be capable of giving informed consent. The University of Chicago referring physician will be contacted for concurrence of agreement.~Exclusion Criteria:~Patients with pulmonary arterial hypertension, but not portopulmonary hypertension will be excluded. Patients will be excluded from consideration if they do not have severe PTPH, if invasive hemodynamic assessment is contraindicated, or if there are any contraindications to sildenafil. Patients with unstable coronary syndromes or otherwise significant unrevascularized coronary artery disease and myocardial ischemia as determined by cardiac stress testing and/or coronary angiography will also be excluded. Moribund patients will not be considered for enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Ankylosing Spondylitis (AS) fulfilling the modified New York criteria~* Active axial disease at Screening and Baseline defined by a Bath Ankylosing~* Spondylitis Disease Activity Index (BASDAI) score ≥ 4 and Total Back Pain ≥ 4~* Failed prior treatment with at least 2 NSAIDs for at least 4 weeks each~* Participant has never received a biologic therapy eg, tumor necrosis factor (TNF) antagonist or monoclonal antibody \[mAb\] against IL-17A (biologic naive main study), or have taken more than one biologic therapy (biologic-failure substudy) for the treatment of AS~Exclusion Criteria:~* Radiographic evidence of total ankylosis of the spine~* Clinically significant back pain caused by diseases other than AS~* Concurrent treatment or treatment within the 6 months prior to Baseline with cell depleting biologic agents~* Participation in any study of an investigational drug, including those for COVID-19~* History of malignancy~* Oral corticosteroids (prednisone or equivalent) \> 10 mg/day systemically for ≥ 2 weeks prior to Baseline Visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Administration of CC-99677 150 mg QD PO (Type: EXPERIMENTAL): 49 participants will be randomized to CC-99677 150 mg in biologic naive main study
- Administration of CC-99677 60mg QD PO (Type: EXPERIMENTAL): 49 participants will be randomized to CC-99677 60 mg in biologic naive main study
- Administration of Placebo QD PO (Type: PLACEBO_COMPARATOR): 49 participants will be randomized to placebo in biologic naive main study
- Administration of CC-99677 150 mg QD PO. (Type: EXPERIMENTAL): 20 participants will be randomized to CC-99677 150 mg in biologic-failure substudy
- Administration of CC-99677 60mg QD PO. (Type: EXPERIMENTAL): 20 participants will be randomized to CC-99677 60 mg in biologic-failure substudy
- Placebo additional dose cohort (Type: PLACEBO_COMPARATOR): 10 participants will be randomized to placebo in biologic-failure substudy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with ST-segment elevation myocardial infarction~* Undergoing primary percutaneous coronary intervention~* Aged between 20 and 80 years~Exclusion Criteria:~* Previous administration of any antagonist of the platelet adenosine diphosphate (ADP) P2Y12 receptor (clopidogrel, prasugrel or ticagrelor)~* History of stroke or transient ischemic attack~* Previous gastrointestinal bleeding within 6 months, bleeding diathesis, platelet count \< 100,000/mm3 or hemoglobin \< 10 g/dl~* Chronic oral anticoagulation treatment~* Contraindication to the antiplatelet treatment~* Severe renal insufficiency (serum creatine\>2.5 mg/dl)~* Severe hepatic dysfunction (serum liver enzyme or bilirubin\>3 times normal limit)~* Sever chronic obstructive pulmonary disease (COPD) or bradycardia~* Body weight \< 50 kg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel 60 mg (Type: EXPERIMENTAL): Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose
- Ticagrelor 180 mg (Type: EXPERIMENTAL): Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patient;~* Diagnosed in one of the participating centers with at least one pelvic mass that is suspected to be of ovarian origin;~* Are to undergo surgery in order to obtain a final histological diagnosis;~* 18 years of age or older.~Exclusion Criteria:~* Pregnant patients;~* Patients aged under 18 years;~* Patients in whom the surgery does not take place, or takes place more than 120 days after RMI and simple ultrasound-based rules are performed;~* Patients with a prior bilateral oophorectomy;~* Patients with insufficient or missing data;~* Patients who do not give or are incapable of giving an informed consent;~* Patients who are not able or willing to travel to the center hospital for additional diagnostic procedures.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- If simple rules are conclusive (Type: OTHER): All patients included will undergo an ultrasound scan in which both the RMI and simple ultrasound-based rules are applied. This scan will take place in the hospital of inclusion. For 80% of all patients, this will be the only intervention.
- If simple rules are inconclusive (Type: OTHER): If the simple ultrasound-based rules, used in the first ultrasound scan, yield an inconclusive result (approx. 20% of all patients), patients are refered to the center hospital to undergo a second ultrasound (by an expert) and a DW-MRI scan. Furthermore, these group of patients will be asked to give an extra blood sample in order to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of Cystic fibrosis~* Chronic hypercapnia on room air in stable condition (PaCO2 between 45 and 55mmHg in two occasions separated by more than 4 weeks)~* Informed consent~Exclusion Criteria:~* Current treatment with non-invasive ventilation~* PaCO2 more than 55 mmHg~* Recent pneumothorax (within past 3 months)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual medical therapy (Type: NO_INTERVENTION): Usual CF care
- Non-invasive ventilation (Type: EXPERIMENTAL): Pressure support ventilator (SAIME,AIROX)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues